1. Home
  2. QLGN vs IVP Comparison

QLGN vs IVP Comparison

Compare QLGN & IVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • IVP
  • Stock Information
  • Founded
  • QLGN 1996
  • IVP 2020
  • Country
  • QLGN United States
  • IVP United States
  • Employees
  • QLGN N/A
  • IVP N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • IVP Diversified Commercial Services
  • Sector
  • QLGN Health Care
  • IVP Miscellaneous
  • Exchange
  • QLGN Nasdaq
  • IVP Nasdaq
  • Market Cap
  • QLGN 2.8M
  • IVP 3.3M
  • IPO Year
  • QLGN N/A
  • IVP 2023
  • Fundamental
  • Price
  • QLGN $3.54
  • IVP $1.66
  • Analyst Decision
  • QLGN
  • IVP
  • Analyst Count
  • QLGN 0
  • IVP 0
  • Target Price
  • QLGN N/A
  • IVP N/A
  • AVG Volume (30 Days)
  • QLGN 9.1K
  • IVP 76.0K
  • Earning Date
  • QLGN 08-13-2025
  • IVP 08-13-2025
  • Dividend Yield
  • QLGN N/A
  • IVP N/A
  • EPS Growth
  • QLGN N/A
  • IVP N/A
  • EPS
  • QLGN N/A
  • IVP N/A
  • Revenue
  • QLGN N/A
  • IVP $15,399,751.00
  • Revenue This Year
  • QLGN N/A
  • IVP N/A
  • Revenue Next Year
  • QLGN N/A
  • IVP N/A
  • P/E Ratio
  • QLGN N/A
  • IVP N/A
  • Revenue Growth
  • QLGN N/A
  • IVP N/A
  • 52 Week Low
  • QLGN $2.85
  • IVP $1.26
  • 52 Week High
  • QLGN $29.44
  • IVP $401.50
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 44.87
  • IVP 46.82
  • Support Level
  • QLGN $3.37
  • IVP $1.51
  • Resistance Level
  • QLGN $3.85
  • IVP $1.76
  • Average True Range (ATR)
  • QLGN 0.23
  • IVP 0.13
  • MACD
  • QLGN -0.03
  • IVP -0.02
  • Stochastic Oscillator
  • QLGN 34.29
  • IVP 18.43

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About IVP Inspire Veterinary Partners Inc.

Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.

Share on Social Networks: